



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Reviewer #1:**

**Specific Comments to Authors:** Tenofovir alafenamide is a novel tenofovir prodrug with improved pharmacokinetics and reduced renal and bone toxicity compared with tenofovir disoproxil fumarate. The findings of the study highlight the potential benefits of switching to tenofovir alafenamide in managing chronic hepatitis B patients with suboptimal response to Entecavir, providing improved treatment outcomes and minimizing long-term safety concerns. The study is well designed and performed. Results are well discussed. After a minor editing, this manuscript can be accepted.

Thank you very much for your comment. I have made a minor editing of the manuscript, please review it.